| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 42.9MM | +4% |
| Gross Profit | 33.8MM | +2% |
| Cost Of Revenue | 9.2MM | +14% |
| Operating Income | -3.2MM | -21% |
| Operating Expenses | 37MM | - |
| Net Income | -3.9MM | -5% |
| R&D | 7.3MM | +4% |
| G&A | 7.5MM | -15% |
| Marketing | 22.2MM | +3% |
| Amortization | 59K | -16% |
| Interest Expense | 1.8MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call
AxoGen, Inc. ( NASDAQ:AXGN ) is possibly approaching a major achievement in its business, so we would like to shine...
Director Gregory Freitag has sold 25,000 shares of Axogen Inc (NASDAQ:AXGN) on March 7, 2024, according to a recent SEC Filing.
There's been a notable change in appetite for AxoGen, Inc. ( NASDAQ:AXGN ) shares in the week since its full-year...
AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript March 5, 2024 AxoGen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.09. AXGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the AxoGen, Inc. 2023 […]
AxoGen ( NASDAQ:AXGN ) Full Year 2023 Results Key Financial Results Revenue: US$159.0m (up 15% from FY 2022). Net loss...
Q4 2023 AxoGen Inc Earnings Call
Company Sees Increased Sales Across Core Segments and Continues to Innovate in Nerve Repair Market
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimate
Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.